Is Tocilizumab Plus Dexamethasone Associated with Superinfection in Critically Ill COVID-19 Patients?

Background: Dexamethasone and tocilizumab are used to treat severely ill COVID-19 patients admitted to intensive care units (ICUs). We explored whether combination therapy increased the risk of superinfection compared to dexamethasone alone. Methods: This observational, retrospective study included...

Descripción completa

Detalles Bibliográficos
Autores principales: Camou, Fabrice, Issa, Nahéma, Hessamfar, Mojgan, Guisset, Olivier, Mourissoux, Gaëlle, Pedeboscq, Stéphane, Minot, Aimée, Bonnet, Fabrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9573530/
https://www.ncbi.nlm.nih.gov/pubmed/36233432
http://dx.doi.org/10.3390/jcm11195559

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9573530/
https://www.ncbi.nlm.nih.gov/pubmed/36233432
http://dx.doi.org/10.3390/jcm11195559

Ejemplares similares